Blood Res.  2025;60:17. 10.1007/s44313-025-00065-7.

Clonal hematopoiesis: elements associated with clonal expansion and diseases

• Ryu G
• Koh Y
• Jaiswal S
• Yoon S

• KMID: 2565746
• DOI: http://doi.org/10.1007/s44313-025-00065-7

Abstract

Clonal hematopoiesis (CH), characterized by the expansion of hematopoietic stem and progenitor cells harboring somatic mutations, has emerged as a significant age-related phenomenon with profound implications for human health. While initially recognized in the 1960s, recent technological advances have revealed its complex nature and widespread prevalence, affecting up to 84% of individuals aged ≥ 70 years. The clinical significance of CH extends beyond its well-established role as a precursor to hematological malignancies, encompassing its association with cardiovascular diseases, chronic kidney disease, and other non-malignant disorders. This comprehensive review synthesizes the current understanding of CH, focusing on recent advances in genetic and molecular mechanisms, particularly the roles of commonly mutated genes such as DNMT3A, TET2, and ASXL1. We address the emerging distinction between myeloid and lymphoid CH, their differential impacts on disease progression, and the complex interplay between CH and inflammation. Special attention is given to newly identified genetic determinants of clonal expansion rates and their implications for disease progression. The review also examines the revolutionary concept of passenger-approximated clonal expansion rate and its utility in understanding CH dynamics. Furthermore, we dis‑ cuss therapeutic strategies targeting inflammatory pathways and their potential in mitigating CH-associated compli‑ cations. By integrating recent findings from genetic, molecular, and clinical studies, this review provides a framework for understanding CH as a systemic condition and highlights promising directions for therapeutic interventions.

Keyword

Clonal hematopoiesis; Inflammatory pathways; Clonal expansion; Genetic mutations

Figure

• 

  Fig. 1 From environmental factors to diseases in CH

• 

  Fig. 2 Elements affecting expansion rate in CH

Reference

References

1. Busque L, Mio R, Mattioli J, et al. Nonrandom X-Inactivation Patterns in Normal Females: Lyonization Ratios Vary With Age. Blood. 1996; 88:59–65. DOI: 10.1182/blood.V88.1.59.59. PMID: 8704202.

2. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012; 44:1179–1181. DOI: 10.1038/ng.2413. PMID: 23001125. PMCID: 3483435.

3. Weeks LD, Ebert BL. Causes and consequences of clonal hematopoiesis. Blood. 2023; 142:2235–2246. DOI: 10.1182/blood.2023022222. PMID: 37931207. PMCID: 10862247.

4. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015; 126:9–16. DOI: 10.1182/blood-2015-03-631747. PMID: 25931582. PMCID: 4624443.

5. Jaiswal S, Fontanillas P, Flannick J, et al. Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. N Engl J Med. 2014; 371:2488–2498. DOI: 10.1056/NEJMoa1408617. PMID: 25426837. PMCID: 4306669.

6. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017; 377:111–121. DOI: 10.1056/NEJMoa1701719. PMID: 28636844. PMCID: 6717509.

7. Kusne Y, Xie Z, Patnaik MM. Clonal hematopoiesis: Molecular and clinical implications. Leuk Res. 2022; 113:DOI: 10.1016/j.leukres.2022.106787. PMID: 35091334. 106787.

8. Uddin MM, Zhou Y, Bick AG, et al. Longitudinal profiling of clonal hematopoiesis provides insight into clonal dynamics. Immunity & Ageing. 2022; 19:23. DOI: 10.1186/s12979-022-00278-9. PMID: 5670ae5d22a24c91b17e0de5cef958b8.

9. Stein A, Metzeler K, Kubasch AS, et al. Clonal hematopoiesis and cardiovascular disease: deciphering interconnections. Basic Res Cardiol. 2022; 117:55. DOI: 10.1007/s00395-022-00969-w. PMID: 36355225. PMCID: 9649510.

10. Wang K, Zhang W, Yi L, et al. The impact of age and number of mutations on the size of clonal hematopoiesis. Proc Natl Acad Sci. 2024; 121:DOI: 10.1073/pnas.2319364121. PMID: 38359296. PMCID: 10895265. e2319364121.

11. Hubbard AK, Brown DW, Machiela MJ. Clonal hematopoiesis due to mosaic chromosomal alterations: Impact on disease risk and mortality. Leuk Res. 2023; 126:DOI: 10.1016/j.leukres.2023.107022. PMID: 36706615. PMCID: 9974917. 107022.

12. Laurie CC, Laurie CA, Rice K, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012; 44:642–650. DOI: 10.1038/ng.2271. PMID: 22561516. PMCID: 3366033.

13. Pershad Y, Mack T, Poisner H, et al. Determinants of mosaic chromosomal alteration fitness. Nat Commun. 2024; 15:3800. DOI: 10.1038/s41467-024-48190-8. PMID: 38714703. PMCID: 11076528. PMID: 1250c0a2d37c41cbad1c671a34d1b82b.

14. Loh P-R, Genovese G, Handsaker RE, et al. Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. Nature. 2018; 559:350–355. DOI: 10.1038/s41586-018-0321-x. PMID: 29995854. PMCID: 6054542.

15. Jacobs KB, Yeager M, Zhou W, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012; 44:651–658. DOI: 10.1038/ng.2270. PMID: 22561519. PMCID: 3372921.

16. Jakubek YA, Reiner AP, Honigberg MC. Risk factors for clonal hematopoiesis of indeterminate potential and mosaic chromosomal alterations. Translational Research: The Journal of Laboratory and Clinical Medicine. 2023; 255:171–180. DOI: 10.1016/j.trsl.2022.11.009. PMID: 36414227.

17. Zekavat SM, Lin S-H, Bick AG, et al. Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nat Med. 2021; 27:1012–1024. DOI: 10.1038/s41591-021-01371-0. PMID: 34099924. PMCID: 8245201.

18. Watson CJ, Blundell JR. Mutation rates and fitness consequences of mosaic chromosomal alterations in blood. Nat Genet. 2023; 55:1677–1685. DOI: 10.1038/s41588-023-01490-z. PMID: 37697102. PMCID: 10562253.

19. Saiki R, Momozawa Y, Nannya Y, et al. Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis. Nat Med. 2021; 27:1239–1249. DOI: 10.1038/s41591-021-01411-9. PMID: 34239136.

20. Warren JT, Link DC. Clonal hematopoiesis and risk for hematologic malignancy. Blood. 2020; 136:1599–1605. DOI: 10.1182/blood.2019000991. PMID: 32736382. PMCID: 8209630.

21. von Beck K, von Beck T, Ferrell PB, et al. Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment. Blood Cancer J. 2023; 13:5. DOI: 10.1038/s41408-022-00773-8. PMID: 36599826. PMCID: PMC9813350. PMID: f5fa66bf091f4276ad1b622ec58806e2.

22. Niroula A, Sekar A, Murakami MA, et al. Distinction of lymphoid and myeloid clonal hematopoiesis. Nat Med. 2021; 27:1921–1927. DOI: 10.1038/s41591-021-01521-4. PMID: 34663986. PMCID: 8621497.

23. Nakao T, Bick AG, Taub MA, et al. Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential. Science Advances. 2022; 8:eabl6579. https://doi.org/10.1126/sciadv.abl6579.

24. DeBoy EA, Tassia MG, Schratz KE, et al. Familial Clonal Hematopoiesis in a Long Telomere Syndrome. N Engl J Med. 2023; 388:2422–2433. DOI: 10.1056/NEJMoa2300503. PMID: 37140166. PMCID: 10501156.

25. Lasho T, Patnaik MM. Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders. Curr Hematol Malig Rep. 2024; 19:35–44. DOI: 10.1007/s11899-023-00719-2. PMID: 38095828.

26. Ferrer A, Mangaonkar AA, Patnaik MM. Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders. Curr Hematol Malig Rep. 2022; 17:61–68. DOI: 10.1007/s11899-022-00662-8. PMID: 35524933. PMCID: 9077347.

27. Nannya Y. Factors associated with clonal hematopoiesis and interaction with marrow environment. J Bone Miner Metab. 2023; 41:380–387. DOI: 10.1007/s00774-022-01380-0. PMID: 36346484.

28. Pich O, Reyes-Salazar I, Gonzalez-Perez A, Lopez-Bigas N. Discovering the drivers of clonal hematopoiesis. Nat Commun. 2022; 13:4267. DOI: 10.1038/s41467-022-31878-0. PMID: 35871184. PMCID: 9308779. PMID: 7cdd08da9e5f4c1dab238047d9bd0d31.

29. Beauchamp EM, Leventhal M, Bernard E, et al. ZBTB33 Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA Splicing. Blood Cancer Discovery. 2021; 2:500–517. DOI: 10.1158/2643-3230.BCD-20-0224. PMID: 34568833. PMCID: 8462124.

30. Bernstein N, Spencer Chapman M, Nyamondo K, et al. Analysis of somatic mutations in whole blood from 200,618 individuals identifies pervasive positive selection and novel drivers of clonal hematopoiesis. Nat Genet. 2024; DOI: 10.1038/s41588-024-01755-1. PMID: 38811842. PMCID: 11176074.

31. Bolton KL, Ptashkin RN, Gao T, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020; 52:1219–1226. DOI: 10.1038/s41588-020-00710-0. PMID: 33106634. PMCID: 7891089.

32. von Bonin M, Jambor HK, Teipel R, et al. Clonal hematopoiesis and its emerging effects on cellular therapies. Leukemia. 2021; 35:2752–2758. DOI: 10.1038/s41375-021-01337-8. PMID: 34215849. PMCID: PMC8249428.

33. Stacey SN, Zink F, Halldorsson GH, et al. Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis. Nat Genet. 2023; 55:2149–2159. DOI: 10.1038/s41588-023-01555-z. PMID: 37932435. PMCID: 10703693.

34. Pasupuleti SK, Ramdas B, Burns SS, et al. Obesity-induced inflammation exacerbates clonal hematopoiesis. J Clin Investig. 2023; 133:DOI: 10.1172/JCI163968. PMID: 37071471. PMCID: 10231999. e163968.

35. Xie X, Su M, Ren K, et al. Clonal hematopoiesis and bone marrow inflammation. Translational Research: The Journal of Laboratory and Clinical Medicine. 2023; 255:159–170. DOI: 10.1016/j.trsl.2022.11.004. PMID: 36347490.

36. Vlasschaert C, Mack T, Heimlich JB, et al. A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic data sets. Blood. 2023; 141:2214–2223. DOI: 10.1182/blood.2022018825. PMID: 36652671. PMCID: 10273159.

37. Walsh K, Raghavachari N, Kerr C, et al. Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans. Frontiers in Aging. 2022; 3:DOI: 10.3389/fragi.2022.841796. PMID: 35821803. PMCID: 9261374. 841796. PMID: 91cc6f1fb0f44f728c443e64a1e07a92.

38. Watson CJ, Papula AL, Poon GYP, et al. The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science. 2020; 367:1449–1454. DOI: 10.1126/science.aay9333. PMID: 32217721.

39. Fabre MA, de Almeida JG, Fiorillo E, et al. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature. 2022; 606:335–342. DOI: 10.1038/s41586-022-04785-z. PMID: 35650444. PMCID: 9177423.

40. Kubota Y, Viny AD. Germline predisposition for clonal hematopoiesis. Semin Hematol. 2024; 61:61–67. DOI: 10.1053/j.seminhematol.2024.01.007. PMID: 38311514. PMCID: 11103258.

41. Weinstock JS, Gopakumar J, Burugula BB, et al. Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis. Nature. 2023; 616:755–763. DOI: 10.1038/s41586-023-05806-1. PMID: 37046083. PMCID: 10360040.

42. Nachun D, Lu AT, Bick AG, et al. Clonal hematopoiesis associated with epigenetic aging and clinical outcomes. Aging Cell. 2021; 20:DOI: 10.1111/acel.13366. PMID: 34050697. PMCID: 8208788. e13366.

43. Mack TM, Raddatz MA, Pershad Y, et al. Epigenetic and proteomic signatures associate with clonal hematopoiesis expansion rate. Nature Aging. 2024; 1–10. https://doi.org/10.1038/s43587-024-00647-7. DOI: 10.1038/s43587-024-00647-7.

44. Chavakis T, Wielockx B, Hajishengallis G. Inflammatory Modulation of Hematopoiesis: Linking Trained Immunity and Clonal Hematopoiesis with Chronic Disorders. Annu Rev Physiol. 2022; 84:183–207. DOI: 10.1146/annurev-physiol-052521-013627. PMID: 34614373.

45. Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019; 366:eaan4673. https://doi.org/10.1126/science.aan4673. DOI: 10.1126/science.aan4673.

46. Nathan DI, Dougherty M, Bhatta M, et al. Clonal hematopoiesis and inflammation: A review of mechanisms and clinical implications. Crit Rev Oncol Hematol. 2023; 192:DOI: 10.1016/j.critrevonc.2023.104187. PMID: 37879493. 104187.

47. Lin AE, Rauch PJ, Jaiswal S, Ebert BL. Clonal Hematopoiesis: Confluence of Malignant and Nonmalignant Diseases. Annual Review of Cancer Biology. 2022; 6:187–200. DOI: 10.1146/annurev-cancerbio-060121-120026.

48. Buttigieg MM, Rauh MJ. Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface. JCO Precis Oncol. 2023; 7:DOI: 10.1200/PO.23.00132. PMID: 37343201. PMCID: 10309572. e2300132.

49. Kaner J, Desai P, Mencia-Trinchant N, et al. Clonal Hematopoiesis and Premalignant Diseases. Cold Spring Harb Perspect Med. 2020; 10:DOI: 10.1101/cshperspect.a035675. PMID: 31615870. PMCID: 7117948. a035675.

50. Jaiswal S. Clonal hematopoiesis and nonhematologic disorders. Blood. 2020; 136:1606–1614. DOI: 10.1182/blood.2019000989. PMID: 32736379. PMCID: 8209629.

51. Abplanalp WT, Schuhmacher B, Cremer S, et al. Cell-intrinsic effects of clonal hematopoiesis in heart failure. Nature Cardiovascular Research. 2023; 2:819–834. DOI: 10.1038/s44161-023-00322-x. PMID: 39196061. PMCID: 11357996.

52. Liu W, Yalcinkaya M, Maestre IF, et al. Blockade of IL-6 signaling alleviates atherosclerosis in Tet2-deficient clonal hematopoiesis. Nature Cardiovascular Research. 2023; 2:572–586. DOI: 10.1038/s44161-023-00281-3. PMID: 37539077. PMCID: 10399458.

53. Tall AR, Fuster JJ. Clonal hematopoiesis in cardiovascular disease and therapeutic implications. Nature Cardiovascular Research. 2022; 1:116–124. DOI: 10.1038/s44161-021-00015-3. PMID: 36337911. PMCID: 9631799.

54. Winter S, Götze KS, Hecker JS, et al. Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche. Leukemia. 2024; 38:936–946. DOI: 10.1038/s41375-024-02226-6. PMID: 38514772. PMCID: 11073997.

55. Cook EK, Luo M, Rauh MJ. Clonal hematopoiesis and inflammation: Partners in leukemogenesis and comorbidity. Exp Hematol. 2020; 83:85–94. DOI: 10.1016/j.exphem.2020.01.011. PMID: 32001341.

56. Kim PG, Niroula A, Shkolnik V, et al. Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis. J Exp Med. 2021; 218:DOI: 10.1084/jem.20211872. PMID: 34698806. PMCID: 8552148. e20211872.

57. Saadatagah S, Ballantyne CM. Clonal hematopoiesis of indeterminate potential and cardiovascular disease. Translational Research: The Journal of Laboratory and Clinical Medicine. 2023; 255:152–158. DOI: 10.1016/j.trsl.2022.08.013. PMID: 36067904.

58. Polizio AH, Park E, Walsh K. Clonal Hematopoiesis: Connecting Aging and Inflammation in Atherosclerosis. Curr Atheroscler Rep. 2023; 25:105–111. DOI: 10.1007/s11883-023-01083-5. PMID: 36808603. PMCID: 10552081.

59. Bick AG, Pirruccello JP, Griffin GK, et al. Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis. Circulation. 2020; 141:124–131. DOI: 10.1161/CIRCULATIONAHA.119.044362. PMID: 31707836.

60. Kessler MD, Damask A, O’Keeffe S, et al. Common and rare variant associations with clonal haematopoiesis phenotypes. Nature. 2022; 612:301–309. DOI: 10.1038/s41586-022-05448-9. PMID: 36450978. PMCID: 9713173.